^
    1m
    Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer (Veracyte Press Release)
    "Veracyte, Inc...today announced that its TrueMRD Monitoring Test has received coverage from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) for patients with muscle-invasive bladder cancer (MIBC). The TrueMRD Test is covered for recurrence monitoring following definitive treatment with curative intent in patients with MIBC. It will be available for clinicians to order on June 1, 2026, marking the commercial launch of Veracyte’s first minimal residual disease (MRD) offering and the only commercially available truly whole-genome MRD test to come to market, expanding the company’s reach into cancer recurrence monitoring."
    Clinical
    |
    TrueMRD